Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Sep. 06, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 6, 2018--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 at 01:40 P.M. ET in New York, NY.
A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage's lead product candidate, ZULRESSO™ (brexanolone injection), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression. For more information, please visit www.sagerx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005905/en/
CONTACT: Sage Therapeutics
Paul Cox, 617-299-8377
Jeff Boyle, 617-949-4256
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Sage Therapeutics
Copyright Business Wire 2018.
PUB: 09/06/2018 04:05 PM/DISC: 09/06/2018 04:05 PM